CA Patent

CA2151044A1 — Novel inhibitors for factor xa

Assigned to Dendreon Pharmaceuticals LLC · Expires 1994-06-23 · 32y expired

What this patent protects

Novel compounds, their salts and compositions related thereto having activity against mammalian fac-tor Xa are disclosed. The novel compounds include peptide aldehyde analogues having substantial potency and specificity as inhibitors of mammalian factor Xa are further disclosed. …

USPTO Abstract

Novel compounds, their salts and compositions related thereto having activity against mammalian fac-tor Xa are disclosed. The novel compounds include peptide aldehyde analogues having substantial potency and specificity as inhibitors of mammalian factor Xa are further disclosed. The compounds are thought use-ful as inhibitors of factor Xa in vitro or as a therapeu-tic agent for the preparation and treatment of conditions characterized by abnormal thrombosis in mammals. In-termediates useful for the preparation of the novel com-pounds are also disclosed.

Drugs covered by this patent

Patent Metadata

Patent number
CA2151044A1
Jurisdiction
CA
Classification
—
Expires
1994-06-23
Drug substance claim
No
Drug product claim
No
Assignee
Dendreon Pharmaceuticals LLC
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.